Head-to-head · WeighScore
GoodRx vs RxPepsDirect
The verdict
GoodRx takes it — 69.6/100 to 68.7/100, but only just.
GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. RxPepsDirect is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GoodRx | RxPepsDirect |
|---|---|---|
| WeighScore | 69.6/100 | 68.7/100 |
| Grade | C | C |
| Scorecard rank | #125 | #146 |
| Semaglutide | Not disclosed | $64/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $299/mo (brand Zepbound) | $84/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 28 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #125 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Graded #146 · C
Strengths
- Industry-lowest GLP-1 pricing: compounded semaglutide from $25/vial, tirzepatide from $45/vial — no subscription or recurring commitment required
- Real 503A telehealth Rx: licensed NP/PA prescribers + MD medical director (Dr. Jonathan Snipes, NPI 1821250077); patient-specific Rx dispensed by
- FedEx overnight shipping at $15 flat; ships pre-reconstituted and includes syringes, alcohol wipes, and reusable cooled travel case
- Independent batch COA testing by Eagle Analytical (FDA-registered, A2LA ISO 17025): 54/54 sterility and endotoxin passes published publicly on
- No subscription required; $39 flat visit fee covers up to 3 peptides per Rx; pay per vial with no ongoing commitment
Where it loses points
- No LegitScript certification; company founded 2026 — no public track record or long-term patient-outcomes data
- Minimal clinical oversight: $39 asynchronous intake form only — no live video consult required, no labs mandated, no monitoring protocol; lowest
- Per-vial pricing makes true monthly cost opaque; every refill costs another $39 visit fee on top of vial price and $15 shipping
- Only 28 states + DC; excludes California, most of the Southeast (AL, AR, GA, MS, NC, SC, TN, VA), and parts of Midwest
- No coaching, labs, dietitian support, or clinical monitoring included at any tier — purely prescription + dispensing
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.